FDA Approves Bevacizumab Biosimilar for 5 Cancer Types
June 28th 2019The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
FDA Grants Priority Review to Niraparib for Late-Stage Ovarian Cancer Treatment
June 25th 2019The FDA has granted a priority review designation to a supplemental biologics license application for niraparib (Zejula) for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 or more prior chemotherapy regimens, and who have either a BRCA mutation or have homologous recombination deficiency (HRD) and progressed >6 months after their last platinum-based chemotherapy.
Oral Rivaroxaban Reduces VTE in Outpatient Treatment of Patients With Cancer
March 9th 2019Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.
FDA Approves Olaparib for First-Line Maintenance in Gynecological Cancer
December 20th 2018The FDA has approved olaparib (Lynparza) as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.
Avelumab Fails to Meet Primary Endpoints in Phase III Ovarian Cancer Trial
November 27th 2018The PD-L1 inhibitor avelumab (Bavencio) did not induce a statistically significant improvement in overall survival or progression-free survival, either alone or in combination with pegylated liposomal doxorubicin (PLD), when compared with PLD alone in patients with platinum–resistant/refractory ovarian cancer.
FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer
November 12th 2018The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Olaparib Significantly Improves PFS in Advanced BRCA+ Ovarian Cancer
November 6th 2018The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
USPSTF Offers Choice in Testing for Women at Average Risk for Cervical Cancer
August 31st 2018New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.
Physicians With Personal Cancer Experience May Recommend Ovarian Cancer Screening Despite Guidelines
August 29th 2018A recent survey of physicians revealed that 17% of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Tumor Treating Fields May Address Unmet Need in Ovarian Cancer Treatment
August 17th 2018The addition of tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, to weekly paclitaxel (Taxol) appeared safe in the treatment of patients with platinum-resistant ovarian cancer.
FDA Approves Bevacizumab Regimen for Ovarian Cancer Treatment After Surgery
June 13th 2018The FDA has approved bevacizumab (Avastin) for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of patients with advanced ovarian cancer following initial surgical resection.